ArticleFrontiers in psychiatry2023
Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership.
Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Factors associated with cannabis use disorder among Australians using prescribed and illicitly-sourced medical cannabis.Drug and alcohol dependence reports · 2025Article
- Effects of Cannabis Use for Medical Symptoms on Cannabis Use Disorder Symptoms: A 24-Month Follow-up Study.American journal of preventive medicine · 2025Article
- The prevalence and correlates of self-reported cannabis use for medicinal, dual and recreational motives in Australia: Findings from the National Drug Strategy Household Survey 2022/2023.Drug and alcohol review · 2025Article
- Sleep, psychological symptoms, and cannabis use before, during, and after COVID-19 "stay-at-home" orders: a structural equation modeling approach.Journal of cannabis research · 2025Article
- Cannabis Use Patterns and Co-Use of Alcohol and Nicotine in Adults Over 50 by Demographic Factors and Medical Cannabis Use.Cannabis (Albuquerque, N.M.) · 2025Article
- Year-Long Cannabis Use for Medical Symptoms and Brain Activation During Cognitive Processes.JAMA network open · 2024Article
- Pleiotropy and genetically inferred causality linking multisite chronic pain to substance use disorders.Molecular psychiatry · 2024Article
- Herbal Cannabis and Depression: A Review of Findings Published over the Last Three Years.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Impact of year-long cannabis use for medical symptoms on brain activation during cognitive processes.medRxiv : the preprint server for health sciences · 2024Article
- Proceedings of the 2023 Cannabis Clinical Outcomes Research Conference.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Background: Evidence for long-term effectiveness of commercial cannabis products used to treat medical symptoms is inconsistent, despite increasingly widespread use. Objective: To prospectively evaluate the effects of using cannabis on self-reported symptoms of pain, insomnia, anxiety, depression, and cannabis use disorder (CUD) after 12 months of use. Methods: This observational cohort study describes outcomes over 9 months following a 12-week randomized, waitlist-controlled trial (RCT: NCT Results: After 12 months of using cannabis for medical symptoms, 11.7% of all participants ( Conclusions: Frequency of cannabis use was not associated with improved pain, anxiety, or depression symptoms but was associated with new-onset cannabis use disorder in a significant minority of participants. Daily or near-daily cannabis use appears to have little benefit for these symptoms after 12 months of use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.